Breast cancer patients with dense breast tissue more likely to develop contralateral disease
Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.
The study, published in the journal Cancer, is among the first to find the association between breast density (BD) and contralateral breast cancer (CBC).
According to study author Isabelle Bedrosian, M.D., a big...
MD Anderson to present Making Cancer History® Seminar in Indian Wells
The University of Texas MD Anderson Cancer Center returns to Southern California this month with its Making Cancer History® Seminar, 3:30-...
Researchers identify ‘synthetic essentiality’ as novel approach for locating cancer therapy targets
A new method has been found for identifying therapeutic targets in cancers lacking specific key tumor suppressor genes. The process, which...
MD Anderson supports World Cancer Day with allies around the globe
In honor of World Cancer Day on Feb. 4, The University of Texas MD Anderson Cancer Center calls for health care providers, organizations, governments and individuals to unite in the common goal of eliminating cancer. Driven to accelerate progress toward Making Cancer History®, MD Anderson is proud to support this global effort.
Organized by the Union for International Cancer Control in 2000, World Cancer Day is a global campaign...
Dr. Stephen Hahn joins MD Anderson senior leadership team
The University of Texas MD Anderson Cancer Center today announced the appointment of Stephen Hahn, M.D., to the senior leadership role of...
MD Anderson and Guardant Health announce partnership to make comprehensive liquid biopsy part of oncology standard of care
The University of Texas MD Anderson Cancer Center and Guardant Health today announced a multi-year partnership designed to accelerate comprehensive...
MD Anderson and Deerfield Management create Vescor LLC to develop novel therapeutics based on inhibiting autophagy for treatment of specific cancers
Vescor LLC, a new company focused on discovery and development of autophagy targeted therapeutics for cancer treatment, has been formed by...